Provides personalized drug testing services, focusing on patient-specific cancer therapies and precision medicine.
Notable Labs, Ltd. operates as a clinical-stage platform therapeutics company focused on pioneering predictive precision medicines for patients battling cancer. Central to its mission is the development of innovative treatments that harness the power of personalized medicine to improve outcomes in oncology.
At the heart of Notable Labs is its proprietary Predictive Precision Medicines Platform (PPMP), which utilizes advanced bio-simulation techniques to forecast a patient's response to specific cancer treatments. By accurately predicting clinical outcomes before treatment initiation, the PPMP aims to revolutionize therapeutic decision-making and streamline the development of tailored therapies for responsive patient populations.
The company's robust pipeline includes promising candidates such as Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor designed to induce cell cycle arrest and apoptosis in various cancer cells, and Fosciclopirox, a pro-drug of ciclopirox targeted for acute myeloid leukemia. These innovative therapies underscore Notable Labs' commitment to advancing precision oncology and addressing unmet medical needs in cancer treatment.
Founded in 2014 and headquartered in Foster City, California, Notable Labs continues to expand its capabilities and forge partnerships within the biopharmaceutical industry. With a strong emphasis on scientific rigor and patient-centric innovation, the company remains dedicated to transforming cancer care through cutting-edge research and therapeutic development.